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Title: “Complete the antibiotic course to avoid resistance”; non-evidence-based 
dogma which has run its course? 
 
Standfirst. Policy makers, educators and doctors should drop the message that 
completing the course prevents antibiotic resistance.  
 
Introduction 
Antibiotics are vital to modern medicine and antibiotic resistance is a global, 
urgent threat to human health. There is an unambiguous relationship between 
antibiotic exposure and antibiotic resistance at the population level1 and in 
individual patients.2 Therefore reducing unnecessary antibiotic use is a key 
measure to mitigate antibiotic resistance. 
Avoiding antibiotic overuse requires healthcare professionals and the public to 
be well informed about antibiotic treatment. The first objective of the World 
Health Organisation (WHO) Global Action Plan is to ‘Improve awareness and 
understanding of antimicrobial resistance through effective communication, 
education and training.’3 
A major theme of public communication about antibiotics is that patients who 
fail to complete prescribed antibiotic courses put themselves and others at risk 
of antibiotic resistance. For example, in materials supporting this year’s 
Antibiotic Awareness Week the WHO advises patients ‘always complete the full 
prescription, even if you feel better, because stopping treatment early promotes the 
growth of drug-resistant bacteria’.4 Similar advice appears in national campaigns 
in Australia,5 Canada,6 the USA,7and for European Antibiotic Awareness week8. 
Without explicitly contradicting this advice, current public information materials 
from the U.S. Centers for Diseases Control and Public Health England and have 
replaced ‘complete the course’ with messages advocating taking antibiotics 
‘exactly as prescribed’.9,10 However, ‘complete the course to avoid resistance’ 
persists in local guidance (e.g. from NHS choices in the U.K,11 and the Mayo Clinic 
in the U.S.12 and in education (in the U.K it is included as fact in the curriculum 
for secondary school children13). The WHO recommends increasing public 
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awareness of the importance of completing antibiotic courses as a strategy to 
reduce antibiotic resistance.14 
The idea that stopping antibiotic treatment early encourages antibiotic 
resistance is false in most situations. Furthermore, it is a significant barrier to 
optimising antibiotic treatment of individual patients. Policy makers, educators 
and doctors should stop using this message when communicating with the 
public. Further, they should publicly and actively state that this was not 
evidence-based and is incorrect.  
Origins of the idea 
Concern that giving too little antibiotic treatment could select for antibiotic 
resistance can be traced back to the dawn of the antibiotic era. 
When Howard Florey’s team treated Albert Alexander’s staphylococcal sepsis 
with penicillin in 1941 they eked out all the penicillin they had (around 4g, less 
than one day’s worth with modern dosing) over a period of four days by 
repeatedly recovering the drug from the patient’s urine. When the drug ran out, 
the clinical improvement they had noted reversed and he subsequently 
succumbed to his infection.15 There was no evidence that this was due to 
resistance but the experience may have planted the idea that prolonged therapy 
was needed to avoid treatment failure. 
Fleming’s early work demonstrated that sensitive bacteria could be 
‘acclimatised’ to penicillin in the laboratory.16 In his 1945 Nobel prize acceptance 
speech, Fleming painted a vivid clinical vignette in which an imagined patient 
with a streptococcal throat infection who takes insufficient penicillin, transmits 
the infection -- now in resistant form -- to his wife, and is thus responsible for 
her subsequent death from antibiotic-resistant disease.17 Fleming advised ‘If you 
use penicillin, use enough!’ Ironically, Streptococcus pyogenes has never 
developed resistance to penicillin, and we now know that for most forms of 
antibiotic resistance which currently threaten patients, selection of resistance in 
the infection being treated is of very limited importance in routine clinical 
practice. 
Antibiotic treatment as a driver of antibiotic resistance 
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The scenario envisaged by Fleming was of target-selected resistance (see box). 
Infections typically begin when a small population of micro-organisms gain 
access to the host and replicate. Genetic mutations conferring antibiotic 
resistance may arise spontaneously during replication and be selected for during 
treatment. Target-selected resistance may occur with inadequate antimicrobial 
dosing or with monotherapy for infections where spontaneous resistant 
mutations arise on treatment such as tuberculosis and HIV. Early tuberculosis 
treatment trials demonstrated emergence of resistance during monotherapy18 
and underpin the need for combination therapy for this disease. Transmission of 
such professional pathogens during or following inadequate treatment may 
allow resistant strains to spread from person to person. Target-selected 
antibiotic resistance is however of very limited relevance to the bacterial species 
now posing the greatest problems due to antibiotic resistance. 
 The main bacterial species in which antibiotic resistance is a clinical threat 
today (e.g. Escherichia coli and the so-called ESKAPE organisms (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter spp, 
Pseudomonas spp, Enterobacter spp.)) are all found harmlessly in us, on us or in 
our environment. They can also act as ‘opportunistic’ pathogens. They are the 
commonest causes of urinary, abdominal and most forms of nosocomial 
infection. When a patient takes antibiotics for any reason, antibiotic sensitive 
species and strains present among commensal flora on their skin or gut or in the 
environment are replaced by resistant species and strains ready to cause 
infection in the future.19 It is now clear that this collateral-selection (see box) is 
the predominant driver of the important forms of antibiotic resistance which 
affect patients today. The longer the antibiotic exposure these ‘opportunist’ 
bacteria are subjected to, the greater the pressure to select for antibiotic 
resistance.2,20 Importantly for these opportunistic pathogens, resistant strains 
are transmitted between asymptomatic carriers, rather than people with disease. 
Furthermore, many resistance-conferring genes can pass easily between 
bacterial strains or species. Thus antibiotic selection may drive outbreaks of 
resistant infections independently of transmission of a specific strain or 
species.21  
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Antibiotic courses; from fear of under-treatment to demonstrable harm 
from over-treatment 
Traditionally, antibiotics are prescribed in courses of recommended durations. 
Fundamental to the very concept of an antibiotic course is the notion that 
treatment for shorter than the course will be inferior. There is, however, a 
striking lack of evidence that currently recommended durations are minimums, 
below which patients will be at increased risk of treatment failure leading to a 
poor outcome. 
Historically, antibiotic course durations were set by precedent, driven by fear of 
under-treatment, with little concern for antibiotic overuse. For many indications, 
recommended durations have got shorter as evidence for similar clinical 
outcomes with shorter courses has been generated (Table 1). However, the 
picture is patchy and complicated by comparisons of new against established 
agents which may have different pharmacological properties (e.g. long-acting 
macrolides vs. short-acting penicillins). For most indications, studies to identify 
the minimum effective treatment duration with commonly used agents simply 
have not been performed.22 For example, pyelonephritis has historically been 
treated for two-weeks. Trials have demonstrated the efficacy of shorter duration 
treatment using quinolones (7-days ciprofloxacin23 and 5-days levofloxacin24) 
but no such data exist for beta-lactams which are the main antibiotic class used. 
Current international guidelines continue to recommend 10-14 days’ treatment 
with beta-lactams, based purely on absence of data for shorter courses.25 In 
contrast, there are very few situations where shorter-duration treatment has 
been shown to have reduced clinical efficacy. A notable example is otitis media 
where 5 days’ treatment is associated with a lower clinical cure rate (66%) than 
10 days (84%) in the under 2 year old age group.26 Even in this situation though 
differences relate to prolongation of symptoms not treatment failure, disease 
recurrence or selection for resistant pathogens. 
For the opportunist pathogens which pose the greatest AMR threat, no 
clinical trial has demonstrated increased risk of antibiotic resistance 
among patients taking shorter duration treatment. 
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The key argument for changing how we discuss antibiotic course durations with 
patients is that shorter treatment is clearly better for individual patients. Not 
only does an individual patient’s risk of resistant infection depend on their 
personal previous antibiotic exposure2,20 but reducing that exposure by using 
shorter duration treatment is associated with reduced risk of resistant infection 
and better clinical outcome. In hospital-acquired pneumonia, for example, 
randomised-controlled trial data indicate that short-duration treatment 
strategies are not only equivalent for clinical outcome but also associated with 
lower rates of infection recurrence and antibiotic resistance.27,28  
It seems highly inappropriate to suggest patients contribute to antibiotic 
resistance by not following advice to complete a ‘course’ of treatment which is 
lacking in evidence, which itself contributes to antibiotic use and hence 
resistance selection both at a population level and in the patient themselves. 
Is the concept of an antibiotic ‘course’ still valid at all? 
The concept of an antibiotic course ignores the fact that patients may respond 
very differently to the same antibiotic treatment depending on diverse patient 
and disease factors. Currently we largely ignore this fact and instead make non-
evidence-based indication-specific recommendations for antibiotic duration at 
the time of diagnosis. This situation is changing in hospital practice where 
biomarkers of treatment response, such as procalcitonin, can guide stopping 
antibiotic treatment.29 Outside hospital, where repeated testing may not be 
feasible, patients may be best advised to stop treatment when they feel better, in 
direct contradiction of WHO advice.4 Of note, a recent clinical trial found that 
using fever resolution to guide stopping antibiotics in community-acquired 
pneumonia halved the average duration of antibiotic treatment with no 
reduction in clinical success.30  
 ‘Complete the course’: a barrier to antibiotic conservation 
The fallacious belief that antibiotic courses should always be completed to 
minimise resistance is likely to be a significant barrier to reducing unnecessary 
antibiotic use both in clinical practice and in developing a research evidence-
base to guide optimal antibiotic use. This idea is deeply embedded and both 
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doctors and patients currently regard failure to complete a course of antibiotics 
as irresponsible behaviour.31,32 
In primary care, strategies have been effective in avoiding unnecessary antibiotic 
courses being started, for example, through enhanced communication training, 
point-of-care tests, and use of delayed prescriptions.33-5 However in secondary 
care, strategies to reduce antibiotic overuse aim to change or ideally stop 
antibiotics 48-72 hours after they have started but are challenging to 
implement36. Reasons for this include diagnostic uncertainty and team behaviour 
but patient and healthcare professional concerns about the risks of incomplete 
treatment are likely to contribute. Designing trials of antibiotic-sparing 
treatment is notoriously difficult37, particularly if participants are invited to 
consent to receiving shortened antibiotic treatment on the basis that this could 
reduce their risk of antibiotic resistance, when they have been taught from 
school level that this increases the risk of resistance.  
What should we advise patients about duration of antibiotic treatment? 
The ‘complete the course’ message has persisted despite good evidence to the 
contrary and previous arguments that it should be replaced.21,38 One reason it 
may be so resilient is that – given the overwhelming threat of antimicrobial 
resistance - it is simple and unambiguous, and the behaviour it advocates is 
clearly defined and easy to carry out. Nevertheless, there is overwhelming 
evidence that, in many situations, stopping antibiotics sooner is a safe and 
effective way to reduce antibiotic overuse. While in hospital practice, daily 
review of the continued need for antibiotics is a cornerstone of antibiotic 
stewardship,39 in primary care, where 85% of antibiotic prescriptions are 
written, no such ongoing assessment of need is attempted. 
There are reasons to be optimistic that the public will accept that ‘complete the 
course to prevent resistance’ is wrong if the medical profession openly 
acknowledges that this is so rather than simply substituting subtle alternatives 
such as ‘exactly as prescribed’. It goes against one of the most fundamental and 
widespread medication beliefs people have which is that one should take as little 
medication as necessary.40 Concerted and consistent efforts have been successful 
in educating the public that antibiotics do not treat viral infections, for example.  
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Research should be undertaken to determine which simple alternative messages 
such as ‘stop when you feel better’ are most appropriate. Until then, public 
education about antibiotics should highlight the fact that antibiotic resistance is 
primarily the result of antibiotic overuse and not prevented by completion of a 
course. The public should be encouraged to recognise that antibiotics are a 
precious and finite natural resource, which should be conserved. This will 
allow patient-centred decision making about antibiotic treatment, where 
patients and doctors can balance confidence that a complete and lasting cure will 
be achieved against a desire to minimise antibiotic exposure unimpeded by the 
spurious concern that shorter treatment will cause antibiotic resistance.   
Key messages  
1) Patients are put at unnecessary risk from antibiotic resistance when antibiotic 
treatment is given for longer than necessary, not when treatment is stopped 
early. 
2) There is no evidence for any common bacterial infection that stopping 
antibiotic treatment early increases a patient’s risk of resistant infection. 
3) Antibiotics are a precious and finite natural resource which should be 
conserved by tailoring treatment duration for individual patients. 
4) Clinical trials are required to determine the most effective strategies for 
optimizing antibiotic treatment durations and which simple alternative 
messages such as ‘stop when you feel better’ are most appropriate. 
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Box 1: Antibiotic resistance selection 
Target-selection. For certain ‘professional’ pathogens, such as Mycobacterium 
tuberculosis, spontaneous resistance-conferring mutants may be selected during 
treatment, can be transmitted before cure is achieved or can re-emerge following 
treatment failure. Other professional pathogens where this may apply include HIV, 
malaria, gonorrhoea and Salmonella typhi. 
Collateral-selection. Many of the bacterial species which live harmlessly in the gut, 
on our skin and mucus membranes, or in the environment can also cause disease as 
‘opportunist’ pathogens. For such organisms, resistance selection occurs 
predominantly during antibiotic treatment of other infections. Resistance in 
opportunists may be passed easily to other strains of the same species of bacteria or 
to different bacterial species. Key examples include methicillin resistance in 
Staphylococcus aureus, Extended-spectrum beta-lactamase producing 
Enterobacteriaceae and carbapenem resistance in Klebsiella pneumoniae. 
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Table 1 
Key indications for which duration of antibiotic treatment has been evaluated by randomised controlled trial 
Indication Treatment, days Key evidence Evidence on resistance 
Standard 
duration  
Evaluated 
duration  
Otitis Media26 10 5 Inferiority of 5 days vs 10 days for clinical failure demonstrated in RCT Similar short term selection of resistance in 
nasopharyngeal organisms.  
Streptococcal 
pharyngitis41 
10 3-6  Comparable effect of 3-6 days oral antibiotics to 10 days penicillin in children 
with streptococcal throat infection in Cochrane review of 20 studies  
Not assessed 
Community 
acquired 
pneumonia30 
7-10 5  Non-inferiority of 5 day course once afebrile and clinical stability improving 
compared with physician guided therapy (median 10 days) for clinical success in 
RCT 
Not assessed within RCT. Beta-lactam 
treatment >5 days associated with greater 
carriage of resistant S. pneumoniae. 
Cellulitis42 7-14 5  Non-inferiority of 5 day course of levofloxacin compared with 10 days for clinical 
resolution in RCT 
Not assessed 
Pyelonephritis
23,24 
14  5-7 Non-inferiority of 7 v 14 days ciprofloxacin for cure15 and 5 days levofloxacin vs 
10 days ciprofloxacin for eradication of infection and clinical cure in RCTs16 
Not assessed 
Nosocomial 
pneumonia27,28 
10-15  7-8 Non inferiority of short course treatment of suspected pneumonia among critical 
care patients for ICU mortality and infection recurrence in RCTs 
Lower risk of further or resistant infection in 
patients receiving shorter duration therapy 
Intra-
abdominal 
sepsis43 
7-14  4  Non-inferiority of fixed 4 day course compared with physician-guided therapy 
(median 8 days) for surgical-site infection, recurrent intraabdominal infection, or 
death in RCT 
Statistically non-significant lower rates of 
extra-abdominal resistant infection in short 
course group 
Note: RCT= randomised controlled trial 
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